“Is it approved?” sounds like a yes or no question. For peptides it almost never is. The same compound can be an approved medicine in one country, still in trials in another and sold as a research compound everywhere else. This guide sorts the compounds people ask us about into three groups, explains what each group means, and covers the point most people miss: approval abroad is not the same as approval in South Africa.
The short version
- Approved medicines have passed a regulator’s review for a specific use somewhere in the world.
- Investigational compounds are still in human trials and have not been approved anywhere yet.
- Research compounds have never been approved as medicines, though some have been studied in people.
- Approval is for a specific product and use in a specific country. It does not carry over to other countries or to other versions of the same molecule.
Three groups, three meanings

Approved somewhere
These compounds have been approved as medicines by at least one regulator, for a defined condition:
- Semaglutide is approved in many countries for type 2 diabetes and weight management, and is available on prescription in South Africa.
- Tirzepatide is approved in many countries for type 2 diabetes and weight management.
- Tesamorelin is approved in the United States for reducing abdominal fat in people with HIV-associated lipodystrophy.
- Bremelanotide, better known as PT-141, is approved in the United States for low sexual desire in premenopausal women.
- Thymosin alpha-1 (thymalfasin) is approved in a number of countries, mainly for hepatitis B, though not in the United States.
- Elamipretide, sold in research as SS-31, received accelerated approval in the United States in 2025 for Barth syndrome.
- Semax and Selank are registered medicines in Russia, and not in most other countries.
Investigational
These are in human trials and have not been approved anywhere yet. The best-known example is retatrutide, which has completed large phase 3 weight-loss trials and is expected to be submitted for approval. Cagrilintide, on its own and combined with semaglutide as CagriSema, is another. Investigational compounds can have very strong human data, sometimes stronger than older approved drugs, but no regulator has signed off on them yet.
Research compounds
These have never been approved as medicines anywhere. Some have human studies behind them, most have mainly animal research. This group includes BPC-157, TB-500, AOD-9604, DSIP, GHK-Cu (as an injectable), MOTS-c, 5-Amino-1MQ and SLU-PP-332. AOD-9604 reached human trials for obesity but did not continue to approval. GHK-Cu is widely used in topical skincare, which is a separate cosmetic category.
Why approval abroad does not settle it here
Approval belongs to a specific product, for a specific use, in a specific country. When a regulator approves tesamorelin in the United States, it approves that manufacturer’s product for that condition there. It does not make every tesamorelin product approved, and it does not make it a registered medicine in South Africa. Here, the reference is the South African Health Products Regulatory Authority, SAHPRA, and its register of medicines.
That is also why every product in our store carries the same label regardless of the compound: the versions we sell are supplied for research use, not as registered medicines. Our guides on what research use only actually means and whether peptides are legal in South Africa cover what that means in practice.
How to use this when you are researching
- Approved somewhere usually means the strongest, most complete human data, including long-term safety.
- Investigational can mean excellent data from recent large trials, with some long-term questions still open.
- Research compound means you should read the evidence carefully and expect most of it to come from animal studies. Our guide on how to read a peptide study helps.
And whatever the status, quality still matters. A certificate showing purity and identity, explained in how to read a certificate of analysis, tells you whether what is in the pen is what the label says.
Frequently asked questions
Which peptides are approved medicines?
Among the compounds people commonly research, semaglutide, tirzepatide, tesamorelin, bremelanotide (PT-141), thymosin alpha-1 and elamipretide (SS-31) have each been approved by at least one regulator, for specific conditions. Semax and Selank are registered in Russia.
Is retatrutide approved?
Not yet. Retatrutide is investigational. It has completed large phase 3 trials and is expected to be submitted for approval, but no regulator has approved it so far.
If a peptide is approved in the United States, is it approved in South Africa?
No. Approval applies to a specific product, use and country. In South Africa, the reference is SAHPRA’s register of medicines.
Has BPC-157 ever been approved?
No. BPC-157 has never been approved as a medicine anywhere. Most of its research is in animals, with only small human reports.
Sources
- South African Health Products Regulatory Authority (SAHPRA). Register of medicines.
- US Food and Drug Administration. Approval records for tesamorelin (Egrifta, 2010) and bremelanotide (Vyleesi, 2019).
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.
This article is for general information only and is not legal or medical advice. Regulatory status changes, so check SAHPRA’s register for the current position.
Browsing by goal? See peptides for libido.
Related reading: PT-141 (bremelanotide) and what the research shows.
For the full picture on local rules, read are peptides legal in South Africa? To see what makes a supplier trustworthy, start with how to read a certificate of analysis.

